Japan is pouring billions of dollars into its burgeoning space industry and easing restrictions on defense exports, efforts designed to build a homegrown aerospace sector filled with domestic startups that have a global reach.

Letara, a Sapporo-based startup developing hybrid propulsion systems for spacecraft, is looking to capitalize on that push. After focusing on hybrid thrusters for small satellites, the company now plans to develop large rocket systems for the space, defense, and security markets, company’s co-CEO Shota Hirai told TechCrunch.

That expansion is being fueled by ¥2.6 billion (~$16 million) in new funding that comes as the startup tries to turn years of academic research and demonstrations into a commercial business. The round was co-led by Headline Asia, JIC Venture Growth Investment and Incubate Fund with participation from strategic investors including NES (Networked Energy Services) Corporation, an energy company; Toyoda Gosei, a Toyota Group supplier of rubber and plastic automotive components; and Frontier Innovations, a Greece-based IT company specializing in data analytics and business intelligence.

“With this round, we will go beyond demonstrating that thruster in space,” Hirai said. “We plan to explore a much wider set of use cases across both the space domain and the defense and security domain, and to develop and propose hybrid rocket systems suited to each of them.”

At the heart of Letara’s technology is a hybrid rocket design that keeps its solid fuel separate from the liquid oxidizer needed for combustion. Inexpensive, widely available materials such as plastic and rubber are used as solid fuel. The company has developed a proprietary manufacturing process that mixes, shapes, and compresses these materials to ensure they ignite reliably and burn consistently. the end result is a system that can deliver more thrust with less waste than traditional hybrid rockets that often use expensive paraffin wax.

The aim is to solve three problems that have so far, limited the use of hybrid propulsion: generating sufficient thrust, maintaining performance and controlling combustion, Hirai said.

There is considerable opportunity if Letara is successful. The global hybrid rocket propulsion market is projected to expand to $2.6 billion by 2032, up from $848 million in 2024, at a CAGR of 15% — a trajectory that points to growing demand for the technology.

Still, Letara isn’t alone in its pursuit. A number of companies are developing hybrid rocket technology, including Japan’s Interstellar Technologies, China’s Galactic Energy, South Korea’s InnoSpace, and Singapore’s Equatorial Space are advancing hybrid rocket technology. German startup HyImpulse and Australian Gilmour Space are also pursuing hybrid rocket technology, while other U.S. companies are developing competing propulsion and launch systems.

Academic roots

The idea for Letara emerged while co-CEOs Landon Thomas Kamps and Hirai were researching rocket propulsion at Hokkaido University. They believed the relative safety and simplicity of hybrid rockets could make the technology useful beyond traditional space programs, particularly as private companies expand into the industry.

The company’s ambitions have grown along with the market. When Letara was spun out of Hokkaido University in 2020, it was focused on developing satellite thrusters.

Since then, the global propulsion market has become more crowded as demand for launch and defense capabilities has grown. Letara is now pursuing opportunities in defense contracts and launch services, in an effort to position itself to compete not just with other Japanese startups, but with companies around the world.

“Large spacecraft need high thrust propulsion as well, especially when they need to go from LEO (low earth orbit) to GEO (geostationary orbit) and get through the high radiation Van Allen belt quickly,” said Hirai. “And of course, there is insane growing demand for launch vehicles.”

Letara is targeting satellite makers and operators, launch companies and governments. It sees commercial satellites as its biggest market for in-space propulsion, while government demand for rocket systems is growing, particularly in Japan. The company says it has already won orders from rocket and satellite companies as well as the Japanese government, although it did not disclose the value of those contracts.

Its next major milestone is an in-orbit firing test with an overseas partner, which Letara sees as a key step toward commercialization. It will also need to establish a repeatable manufacturing process, backed by quality controls, and a reliable supply chain for fuel and tanks that can support production at scale.

When asked whether recycled plastic could eventually be used as fuel, Letara said it was “very much a possibility” with its hybrid technology, though more testing and development would be needed.

Michael Polansky is remarkably unassuming for someone operating in a corner of the world known for outsize egos.

Seated at a leafy patio outside a popular bakery in Mill Valley, an affluent town about 15 miles north of San Francisco, Polansky — bespectacled, his fresh face framed by dark hair shot through with gray — has the look and the friendly demeanor of a young professor.

He is, in fact, both the founder of a buzzy AI and biology startup called Outer Biosciences and the creative, business, and romantic partner to Stefani Germanotta — better known as Lady Gaga. It’s an unlikely double life. On the one hand, the couple invariably moves in the world that comes with celebrity; on the other, he’s running an outfit that has spent years figuring out how to keep living human tissue alive outside the body — for over a month, so far — without anyone outside the company knowing.

He didn’t see any of it coming. Polansky grew up in Minnesota and went on to Harvard, where he studied applied mathematics and computer science, graduating in 2006. Afterward, he logged three years at the hedge fund Bridgewater Associates — “a very unique place,” Polansky says over coffee, and one where he had “a really good experience,” even if it wasn’t a place he was going to “wake up and be excited about . . .every day.”

His pilgrimage from Bridgewater to Silicon Valley ran through Minnesota. By coincidence, Sean Parker’s assistant at the time had been Polansky’s neighbor growing up. At a 2007 wedding in their home state, she mentioned that Parker was looking for someone to work with him. Polansky already knew who Parker was and was looking to move west. The two had dinner in New York, “hit it off immediately,” and, as Polansky tells it, he quit Bridgewater the next day and moved to San Francisco.

He first landed a role as a principal at Founders Fund when the firm was run by its four original partners — Peter Thiel, Sean Parker, Luke Nosek and Ken Howery – with Polansky and another young principal at the time, Brian Singerman, sharing an office. “It was a really, really great experience,” Polansky says.

When Parker left Founders Fund after becoming liquid in his Facebook stock and wanted to build out his own family office, he brought Polansky with him. Polansky ran that office — handling Parker’s business, investment, and philanthropic interests, including helping stand up the Parker Institute for Cancer Immunotherapy (where Polansky remains executive director) until COVID, when his life “moved in a different direction.”

That change had a lot to do with Germanotta. Polansky met her in late 2019 at one of Parker’s birthday parties. Charmingly, the meeting came at the urging of her mother, Cynthia Germanotta, president of the Born This Way Foundation, whom Polansky had come to know through his philanthropic work.

“She had said, you know, for months and months, ‘I want to set you up with my daughter,’” Polansky recalls. “I was like, I think you’re making fun of me.” She wasn’t. When their own mothers later met, he says, laughing, “it all made perfect sense.” (His mother and Germanotta’s mother are now close friends.)

Their relationship is a full partnership, professionally and personally. Notably, for Gaga’s most recent world tour, which began in July of last year and ended in April, the couple managed a massive operation across three 747s, something Polansky compares to running “a 200-person startup that travels around the world every day.”

It also includes Haus Labs, the cosmetics brand Germanotta initially built “on her kitchen floor,” Polansky says, instead of simply licensing her name to an existing company. That business, based in El Segundo, California, an operation with roughly 70 employees, is reportedly thriving.

Germanotta also sits on the board of Outer Biosciences, and the two companies collaborate at the margins. For example, Outer Biosciences’ chief scientist, Kyung-Jin Jang, sits on Haus Labs’ scientific advisory board, and the companies have run some joint projects.

Says Polansky, beaming as he talks about her from our sun-dappled table: “People really haven’t gotten to know a certain side of her publicly … She’s such a brilliant businessperson.”

From cancer to tissue in a dish

While Polansky is also a businessperson, he’s not a scientist. He got into life sciences “accidentally,” he says, through more than a decade spent alongside Parker in cancer immunotherapy, a field that was “very fringe” when they entered it.

Outer Biosciences, which Polansky founded in 2022 and where he is CEO, grew out of frustration that the pace of innovation in biology and chemistry has never matched software, in large part because there’s no ethical way to run experiments directly on people. Meanwhile, the proxies scientists rely on instead — animal models, simplified cell cultures, lab-grown organoids — are poor stand-ins for how a real human organ behaves.

So Outer Biosciences took a different approach. Instead of engineering a synthetic organ, the company sources human skin that would otherwise be discarded after surgery – mostly plastic surgery – through what it describes as vetted non-profit and commercial biobanks and brokers operating under “institutional review board oversight and documented donor consent,” principally the National Disease Research Interchange and the Cooperative Human Tissue Network. (Both outfits receive federal funding from the NIH and the National Cancer Institute without being federally operated.)

Polansky is careful to note that there is no single government tissue network that qualifies buyers. He says Outer Biosciences pays fees to these suppliers on a cost-recovery basis rather than purchasing tissue outright. He also says the company spent roughly two years on building that pipeline and handling the protocols required to receive that tissue “within hours” of surgery, while it’s still living.

Asked about the donors’ privacy, he says that every sample arrives already de-identified — stripped upstream by the supplying organizations of names, contact information and other direct identifiers. A proprietary support system developed by his team then feeds the tissue nutrients and removes metabolic waste, extending its viable life well past the industry norm.

That norm, by the way, is a matter of days. That’s enough time to test for acute toxicity, but not for slower biological processes like collagen remodeling, pigmentation change, or barrier repair that take weeks to unfold. (Dermatologists routinely tell patients to expect changes over a matter of weeks for this same reason.)

Outer Biosciences’ system meanwhile keeps tissue alive for up to a month, says Polansky, who says it retains its “day-zero architecture and preserves its day-zero epidermal, stromal and immune-associated molecular programs.” In plainer English, that means that 30-day-old tissue cared for by the company looks a lot like day-one tissue, but it isn’t fully indistinguishable from it.

Sunburn is one of the clearer examples of what that extra time buys Outer Biosciences. Polansky says that its researchers can induce UVB damage in living tissue, then track the stress, inflammatory, and recovery-related responses that follow over the following weeks as an information-gathering exercise. He says the team isn’t “healing” the skin but rather watching an injury happen and then watching the biology that follows it over time.

Perhaps anticipating pushback from the scientific community, Polansky is careful about how he frames the company’s achievements when this reporter asks questions about rival technologies. The startup’s value, he says, isn’t any one piece of what it’s doing but how the pieces fit together: human tissue that can be kept alive for weeks, a diverse donor pool that Outer Biosciences’ team can subject to controlled experimental conditions, and repeated molecular measurements taken along the way.

And it’s all fed into one, closed self-enforcing system. An AI model predicts which untested chemicals are likely to have a beneficial effect on a specific skin function. Those chemicals get run through the living-tissue system. Then the results, whether the prediction was right or wrong, get fed back into the model, improving the next round of guesses.

It’s a giant improvement from where things started, says Polansky. Early on, the company relied on a “brute force” approach, mining scientific literature and partnering with the National Cancer Institute on natural compounds from extreme environments. That phase produced a couple of leads over about 18 months, but with AI layered in, the company is now generating a new candidate roughly every six weeks, with six leads currently active in its pipeline and several dozen additional “hits” logged.

What makes that pace truly astonishing, Polansky says as the crowd around us thins out, is the size of the current universe of skin-active ingredients.

It’s almost impossible to know the exact number, but it’s small. “Active ingredient” means something different informally than it does formally. While the FDA maintains rules covering 13 categories of over-the-counter skin drugs (think sunscreen, antifungals), across all of them, only about 120 to 130 active ingredients are approved. Add cosmetic ingredients backed by actual research, says Polansky, and that number is closer to 200.

This, of course, presents opportunities.

Outer Biosciences is discovering cosmetic ingredients, not drugs, so there’s no FDA approval to seek out. Instead, the route runs through two steps: first, getting the ingredient a standardized industry name; then safety testing under guidelines set by the OECD, a Paris-based international body whose member countries agree to accept each other’s properly run studies — meaning a study done correctly in one participating country is accepted in the other 40-plus.

A partner outfit then commercializes the whole thing. Indeed, rather than build its own consumer brand, Outer Biosciences right now plans to license or sell its finished ingredients to beauty or pharma outfits that will then formulate these into actual products (a serum, a cream) and bring them to market under their own brands. Already, four of Outer Biosciences’ six current leads look likely to reach commercialization, Polansky says.

In the meantime, the company is generating money from collaborative research partnerships, including a pharmaceutical partner that’s studying why certain cancer drugs cause severe skin rashes, and consumer beauty brands that are testing whether Outer Biosciences’ data holds up against their own product-development and marketing needs.

If Polansky is raising more money for the company currently, he won’t say. To date, the company has raised roughly $23 million, with early backers including Calm Capital, Brighter Capital and Polansky’s own investing firm, Hawktail, among others. The company employs 19 people, with all but Polansky based just outside Cambridge, Massachusetts.

Asked why he’s chosen now to talk about the company after years of near-total silence — he says he barely discussed it even with close friends — Polansky points to the data the team is beginning to amass and the confidence that has given them. “Trying to do this in private is hard,” he says, as the wait staff start flipping chairs onto tabletops, signaling it’s closing time at the bakery. “We kind of want to start working in public now,” he adds, shrugging.

Outer Biosciences is not the only company chasing this idea, even if its use of real tissue, rather than synthetic, is distinctive.

Vivodyne — a Philadelphia-based competitor building lab-grown human organ tissue paired with predictive AI to replace animal drug testing — just this month announced it has raised close to $80 million to date, including a $38 million seed round and a $40 million Series A, both led by Khosla Ventures.

Other rivals are pursuing various flavors of organ-on-a-chip and microphysiological systems for preclinical testing.

Polansky doesn’t seem especially preoccupied with any of them — less, it seems, out of arrogance than because he seems to have his hands full. Besides, there’s plenty of room for everyone in this moment. Unlike AI companies training on scraping the internet, there is no “biology internet” to scrape.

And Outer Biosciences has two other reasons to focus on its own knitting. First, the data it generates doesn’t exist anywhere else, which, conceivably, makes the company’s position more defensible, if a lot slower, to build than “traditional” software-based AI startups. It’s also cheaper to run, with modest compute demands compared with training a large language model. In fact, all of the company’s AI work currently runs on-premise, not in the cloud, because “we don’t want the data in the cloud,” Polansky says.

Whether over time, Outer Biosciences becomes a standalone commercial-ingredients business, licenses its discoveries, or eventually reorganizes around a single breakout compound, Polansky says he hasn’t settled on – and the team doesn’t need to. The more important goal, he says, is a predictive model that’s accurate enough that the company can spot promising directions in skin biology without having to run every experiment physically first, opening up a rate of discovery in dermatology that doesn’t currently exist.

For now, instead, the work of turning a promising compound into a real product — the formulation, the manufacturing scale-up, the supply chain, the safety testing — is still done manually by the same scientists who discover the compounds in the first place. Building out a product-development team, with people who’ve done this kind of work before, is next on the roadmap.

“I think it’s going to be fun,” he says, “to have people know that this is what we’ve been doing.”

Summer has persisted across the country, with high temperatures lingering far into the season’s last weeks. Cool food feel like a necessity rather than a luxury. Store-bought pints have escalating prices, fewer choices, and ingredient labels that frequently leave little room for personal preference. A machine that lets you decide every element of the frozen dessert starts looking practical rather than optional. Ninja’s Creami XL 11-in-1 (model NC601), priced at $186.99 after clipping the on-page coupon (was $250), builds on the earlier Creami formula with larger 24-ounce tubs that hold about 50 percent more than the original pints.

The box contains two tubs that serve as a good starting point. You make a base, freeze it for a day until it solidifies, and then put it in the machine. The Creamerizer, a special paddle that spins through the frozen block, swiftly converts it into a smooth, scoopable ice cream. You can respin it to make it softer. The approach is simple: prepare ahead of time, freeze, spin, and serve; however, with family-size capacity, the math changes slightly.

Sale

Ninja Creami XL 11-in-1 Ice Cream Maker with XL Capacity, NC601

• NEW FUNCTIONALITY: Turn almost anything into crave-worthy ice cream, sorbet, frozen yogurt, and more. Now featuring dairy-free, smoothie bowl, and…
• FAMILY-SIZE CAPACITY: Each 24-oz XL tub holds 50% more than the original Creami pint. Process both and make enough ice cream for the whole family.
• TWO FLAVORS, ONE TUB: Process one frozen base with two different mix-ins to create two unique flavors in one tub. One for the chocolate lover, one for…

One tub is plenty for many servings. Process both tubs, and you’ll have enough for a small group or to stock the freezer for the week. Many people who have a high-protein dessert every afternoon after a workout or a long day remark that the larger amount allows them to avoid continuously prepping. When you keep two solid bases in the freezer at all times, meal planning becomes much easier.

Eleven one-touch programs cover the bases and then some. There are the traditional suspects, such as ice cream, low-fat ice cream, sorbet, gelato, frozen yogurt, milkshake, and frappe, but there are also more recent additions that tick a lot of boxes. Dairy-Free is ideal for using almond, oat, or coconut milk bases, and it really delivers. Smoothie Bowl produces thicker, spoonable fruit blends that are ideal for breakfast or post-workout nutrition, while CreamiFit deals with protein-rich mix-ins prepared from powder, Greek yogurt, cottage cheese, or ultra-filtered milk. Many customers believe that these applications are a must-have upgrade since they lessen the number of frozen spots and eliminate the need for further spins.

The machine’s true power comes from its capacity to handle ingredients. You can choose milk or an alternative, sweetener, protein source, and flavor. It’s excellent for making low-sugar, dairy-free, keto-friendly, or completely indulgent versions all in one machine. You can also add other ingredients at the end, such as chocolate chips, almonds, fresh fruit, brownie pieces, or candies, without turning everything into mush. One frozen foundation can even hold two separate mix-in amounts in the same tub, allowing one person to enjoy chocolate peanut butter and another to have strawberry.

Cleaning the thing is simple because all of the parts fit on the top rack of the dishwasher. The machine itself has a sleek, modern appearance with a blue finish and a footprint that fits beneath most cabinets once the spinning is completed. It isn’t precisely whisper quiet, but the quick processing time limits the noise to a minimal.

Compared to purchasing a host of specialty pints for $6 to $9 each, the machine will pay for itself in one season of regular use. The ongoing expense is the freezer space; larger tubs take up a lot of space, so if you live alone or do a lot of solo cooking, the original size may be a better option, but for everyone else, it’s a game changer. Simply prepare a couple of bases this weekend, and by Monday, you’ll have a batch of ready-to-spin ice cream according to your preferences.

Google is giving students a free year of its Gemini subscription, although the exact plan students receive depends on where they live. US students can claim the more capable Gemini Pro plan, while students elsewhere can get Gemini Plus for 12 months.

The offer is available to students worldwide and runs until December 31, 2026. To claim it, students need to choose their preferred plan through Google’s promotional offer page, verify their student status through SheerID and add a payment method.

For the longest time, the tech industry’s unofficial motto was “if the product is free, you are the product.” Most of us just accepted it. But after a decade of data scandals, tracking revelations, and privacy blunders, that logic is starting to feel dated.

We’ve hit a tipping point. A quiet but powerful shift is happening across the software landscape, and in 2026, privacy is no longer a dusty toggle buried in the settings menu. It’s becoming the main event, a core selling point that companies are building their reputations on.

So where is this privacy-first shift most obvious? These are the software categories where the change is easiest to spot, and the clearest signs that your data is finally getting a bit more respect.

1. Browsers: Moving Beyond ‘Incognito’ Theater

Finally, a private window that’s actually more private.

Let’s be honest: everyone knew “Incognito mode” was limited. It never stopped your ISP, your employer, or the websites you visited from seeing what you were up to. Users are demanding more now, and browser makers are listening.

You’re seeing a surge in browsers like Brave and the DuckDuckGo browser, which block ads and trackers by default. Even the big players are changing course. Mozilla has kept expanding Firefox’s privacy tools, and the industry is exploring standards such as Private Access Tokens to verify legitimate users with less tracking. That’s a real step up from a feature that mostly hid your search history from whoever else used the same laptop.

2. Messaging Apps: Locking the Digital Diary

Your chats are increasingly for your eyes only.

Remember when private messages could be scanned to sharpen ad targeting? Creepy, right? The backlash against that model came fast, and it fueled the growth of private platforms like Signal.

That pressure has pushed bigger platforms to adapt. WhatsApp has rolled out stronger privacy controls, including view-once messages, while continuing to lean on end-to-end encryption. With governments still debating whether companies should scan private messages, secure communication has gone from a nice-to-have to a necessity.

3. VPNs: The New Gold Standard for Trust

Putting the “private” back in Virtual Private Network.

The VPN industry has long had a trust problem. For every strong service, there are plenty of questionable ones with vague “no-logs” claims that fall apart under scrutiny. Reports of VPNs handing user data to police and free apps leaking user data have left people understandably skeptical.

So how do you fix a trust problem? You stop saying and start proving. A new gold standard is emerging around verifiable evidence, and it’s pushing the market to clean up its act.

Top-tier providers are moving toward verifiable proof to regain user trust. Independent no-logs audits, such as those conducted for providers like IPVanish and ExpressVPN, are becoming mandatory baselines. At the same time, major services are actively transitioning to RAM-only server networks, where operational data is automatically erased upon every reboot rather than stored on persistent hard drives. Combined with regular transparency reports, this mix of third-party auditing and ephemeral infrastructure is becoming the benchmark users check when weighing up a secure VPN for privacy.

4. AI Tools: Personalization Without the Peeking

Smart assistants that don’t need your full life story.

With AI exploding, the next privacy battleground is already here. Can you get smart, personalized AI without it hoovering up every scrap of your personal data? A new wave of tools suggests the answer might be yes.

There’s a growing push toward on-device processing, where AI models run locally on your phone or laptop, as seen in Apple’s recent OS updates. Private AI platforms like Jatter use client-side encryption to offer personalized responses without storing conversation histories on remote servers. It’s still early, but it’s a promising sign that privacy-focused thinking is spreading to the next generation of software.

So, what’s the takeaway?

The overarching message is clear: privacy has evolved from a regulatory hurdle into a core product strategy and a primary competitive advantage. The software platforms built on unchecked data collection are now forced to compete on verifiable trust and structural transparency. In 2026, protecting user data is no longer just ethical, it’s good business.

OLED has spent the past few years getting substantially brighter while Mini LED and the newer RGB backlit LCD technologies have attacked it from the other direction with enormous screens, extreme brightness and increasingly impressive color performance. LG Display apparently has no intention of letting that become a one-sided fight.

The company has unveiled FLiPP, short for FMM Less innovative Pixel Patterning, a new manufacturing process that eliminates the fine metal masks traditionally used to create red, green and blue OLED pixels. LG Display says the process can improve brightness, panel lifespan and power efficiency while also making OLED manufacturing more flexible and potentially less expensive.

Before anybody starts clearing wall space for a 100 inch FLiPP OLED, there is an important qualification: LG Display has not announced a FLiPP television or a commercial TV launch date. The company says the technology will initially target IT products including tablets and monitors before eventually expanding into everything from 1 inch wearable displays to ultra large TVs. So this is not your next LG OLED TV, but it could have a lot to do with what comes after it.

What Is FLiPP?

Conventional RGB OLED production commonly relies on a Fine Metal Mask, or FMM, during manufacturing. The easiest way to visualize it is as an extremely precise stencil: red, green and blue organic materials are deposited through microscopic openings in the mask so they land in the correct locations on the panel.

That approach works, but it comes with some expensive baggage. Different panel sizes and resolutions can require different masks, and as those masks become larger, gravity becomes an engineering problem. The metal can sag toward the center, making precise alignment more difficult and potentially creating defects including unwanted color mixing.

FLiPP removes the metal mask entirely. Instead, LG Display applies and positions the RGB OLED materials and then uses photolithography with precision ultraviolet light to remove material from areas where it is not required. The result is more usable pixel area and fewer of the physical limitations imposed by FMM manufacturing.

LG Display says FLiPP improves the aperture ratio by approximately 55 percent compared with conventional FMM manufactured OLED panels. Aperture ratio refers to how much of the display’s available surface is actually occupied by active red, green and blue pixels. More active emitting area gives engineers considerably more room to balance brightness, efficiency and longevity.

The Numbers Are Impressive, With an Asterisk

LG Display says FLiPP can enable OLED panels to deliver up to 1.6 times higher brightness, 2.4 times longer lifespan and 13 percent lower power consumption compared with panels produced using FMM under comparable conditions. Those are significant numbers, but they should not be interpreted as a promise that some future television will automatically be 60 percent brighter, last 140 percent longer and consume 13 percent less electricity simultaneously.

OLED panel designers can trade efficiency gains between brightness, power consumption and longevity depending on the product being developed. In other words, these are development and manufacturing advantages that give LG Display considerably more room to decide where that additional performance goes. That flexibility may ultimately matter more than any one headline specification.

Manufacturing May Be the Bigger Story

Brightness is going to grab the headline, but manufacturing efficiency could ultimately have a greater impact on consumers. LG Display says it has successfully produced FMM less OLED using an entire 8.5 generation mother glass substrate, rather than cutting the substrate into smaller sections to accommodate the physical limitations of metal masks.

For laptop sized OLED panels, LG says FLiPP can provide up to 64 percent higher mother glass utilization efficiency compared with FMM production or other FMM less methods that require divided substrates. That means less wasted material and potentially higher production output from the same basic sheet of glass.

Lower manufacturing cost does not automatically mean lower retail prices. Anyone who has purchased a flagship television recently has probably noticed that manufacturers remain quite capable of finding somewhere else to spend the savings. But improved yields, fewer specialized masks, better substrate utilization and greater flexibility in panel size all create the conditions necessary for RGB OLED to scale more economically.

And scale has been one of OLED’s biggest problems.

Why This Matters for TVs

We recently looked at the increasingly complicated fight between OLED, Mini LED and RGB backlit LCD TVs, and 2026 has made one thing fairly obvious: premium LCD is not quietly going away. Hisense, Samsung, TCL, Sony and LG have all pushed RGB based backlighting as a way to extract higher brightness, broader color reproduction and very large screen sizes from LCD, while LG itself now sells Micro RGB evo televisions alongside its OLED lineup.

Meanwhile, LG Display’s current Tandem WOLED technology has pushed OLED brightness significantly higher. Its latest Primary RGB Tandem 2.0 TV panel is rated by LG Display for peak brightness of up to 4,500 nits under its specified test conditions, while retaining OLED’s pixel level light control and perfect black capability.

FLiPP attacks a different problem. Rather than adding another layer or changing the television’s processing, it changes how RGB OLED panels can be manufactured in the first place. LG Display says the technology is theoretically scalable from approximately 1 inch to 100 inches, without being tied to the same FMM size and resolution restrictions.

That could eventually make large format RGB OLED far more practical, which is important because the premium television battle increasingly comes down to compromises. OLED still delivers exceptional black levels, pixel level illumination and wide viewing angles, while RGB Mini LED and Micro RGB LCD televisions can push brightness considerably harder and scale to enormous sizes, but still require an LCD layer and local dimming system.

A manufacturing process that allows RGB OLED to become brighter, more efficient, longer lasting and easier to manufacture at much larger sizes would change that equation. LG still has to prove FLiPP can deliver those advantages at commercial yields and consumer friendly prices, but the potential is substantial.

What Happens Next?

LG Display demonstrated FLiPP at IMID 2026 in Busan, South Korea, where the company described it as a new OLED manufacturing platform rather than a single product technology. The first intended applications are tablets and monitors, with LG Display saying it plans to expand the process into additional display categories later, including wearables, VR and AR hardware and eventually ultra large televisions.

There is currently no announced FLiPP TV model, price or consumer availability date. That makes this considerably less exciting for anyone shopping for a television this weekend, but potentially far more important for where OLED goes over the next several years.

The Bottom Line

The television industry has spent the past two years making LCD technology behave more like OLED. RGB Mini LED and Micro RGB displays have dramatically improved color reproduction, brightness and local dimming while pushing screen sizes well beyond what most OLED buyers can currently afford.

FLiPP suggests OLED manufacturers may have another answer. By eliminating the Fine Metal Mask from RGB OLED production, LG Display believes it can improve usable pixel area, reduce manufacturing constraints and give panel designers significantly more flexibility with brightness, lifespan, power consumption and screen size.

The technology still has to make the jump from impressive manufacturing demonstration to high volume consumer product, but if LG Display can make FLiPP work economically at television scale, the next battle between OLED and RGB backlit LCD may look very different. Just don’t postpone buying a television because somebody put “100 inch OLED” in a headline. We are not there yet.

Reference: lgdisplay.com

Related Reading:

Nintendo has just confirmed an official price rise on the Switch 2 is coming on September 1, upping the RRP on the console to £419. However, we’ve found to beat the rise.

But right now, you can grab it before the price rise lands and get the Nintendo Switch 2 for £344.99, down from its £395.00 list price via a £20.01 site discount stacked with a £30.00 coupon, a saving that pushes the total reduction past £50.